BKM120: Clinical Trials

3 trials of BKM120, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Completed 2, Terminated 1
Phase 21Completed 1

Follow BKM120: new trials by email Literature Review of BKM120 trials Research Report on BKM120

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Fulvestrant, BKM120, BKM120 matching placebo - Metastatic Breast Cancer
Phase 3TerminatedNovartis Pharmaceuticals4322012-10-032019-01-30
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Fulvestrant, BKM120, BKM120 matching placebo - Breast Cancer
Phase 3CompletedNovartis Pharmaceuticals11472012-08-072020-08-25
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Paclitaxel, BKM120 matching placebo, BKM120 - Breast Cancer
Phase 2 / Phase 3CompletedNovartis Pharmaceuticals4162012-08-012017-03-09

Conditions studied

Breast Neoplasms (3)  ·  Neoplasm Metastasis (3)  ·  Hereditary Sensory and Autonomic Neuropathies (2)

Sponsors

Novartis Pharmaceuticals (3)

Countries

Austria (3)  ·  Belgium (3)  ·  Canada (3)  ·  France (3)  ·  Germany (3)  ·  Hungary (3)  ·  Italy (3)  ·  Netherlands (3)  ·  South Korea (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  Brazil (2)

Results publications

PMID 28576675, PMID 29223745, PMID 30241001